Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Related Pruritus: A Prospective, Randomized Control, Double-blinded, Phase II Clinical Trial

Trial Profile

Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Related Pruritus: A Prospective, Randomized Control, Double-blinded, Phase II Clinical Trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2016

At a glance

  • Drugs Aprepitant (Primary) ; Desloratadine
  • Indications Pruritus
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top